Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18:v1–75.

Article  PubMed  PubMed Central  Google Scholar 

Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50–8.

Article  CAS  PubMed  Google Scholar 

Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012;2012:831090.

Article  PubMed  PubMed Central  Google Scholar 

Shahar T, Nossek E, Steinberg DM, Rozovski U, Blumenthal DT, Bokstein F, et al. The impact of enrollment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci. 2012;19:1530–4.

Article  PubMed  Google Scholar 

Roger Stupp MDWP, Michael Weller MDBF, Karl Belanger MDAA, Ulrich Bogdahn MDJC, Samuel K, Ludwin MDTG, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;9:196–7.

Google Scholar 

LISA M. DEANGELIS MD. Brain tumors. N Engl J Med. 2001;344:114–123.

Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G, Vecht C. Glioblastoma in adults. Crit Rev Oncol/Hematol. 2008;67:139–52.

Article  PubMed  Google Scholar 

Ortiz R, Perazzoli G, Cabeza L, Jimenez-Luna C, Luque R, Prados J, et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19:513–37.

CAS  PubMed  PubMed Central  Google Scholar 

Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin Cancer Res. 2020;26:1690–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu, W., Zhang, L., Wei, Q. & Shao, A. O. (6)-Methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2019;9:1547.

Beig N, Patel J, Prasanna P, Hill V, Gupta A, Correa R, et al. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Sci Rep. 2018;8:7.

Article  PubMed  PubMed Central  Google Scholar 

Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352:997–1003.

Article  CAS  PubMed  Google Scholar 

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a state of the science review. Neuro-oncology (Charlottesville, Va.). 2014;16:896–913.

Article  CAS  Google Scholar 

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707–18.

Article  PubMed  Google Scholar 

Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74:1886–90.

Article  CAS  PubMed  Google Scholar 

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LJ, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110:6021–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013;126:267–76.

Article  CAS  PubMed  Google Scholar 

Huang LE. Impact of CDKN2A/B homozygous deletion on the prognosis and biology of IDH-mutant glioma. Biomedicines. 2022;10:246.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen J, Hodges TR, Song R, Gong Y, Calin GA, Heimberger AB, et al. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018;57:137–41.

Article  CAS  PubMed  Google Scholar 

Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK, et al. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun. 2020;11:3811.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020;20:57–70.

Article  CAS  PubMed  Google Scholar 

Zhou W, Wahl DR. Metabolic abnormalities in glioblastoma and metabolic strategies to overcome treatment resistance. Cancers (Basel). 2019;11:1231.

Article  CAS  PubMed  Google Scholar 

Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, et al. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell. 2022;40:939–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, et al. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 2022;40:957–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou W, Zhao Z, Lin A, Yang JZ, Xu J, Wilder-Romans K, et al. GTP signaling links metabolism, DNA repair, and responses to genotoxic stress. Cancer Discov. 2023;14:158–75.

Article  Google Scholar 

Shireman JM, Atashi F, Lee G, Ali ES, Saathoff MR, Park CH, et al. De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. Brain. 2021;144:1230–46.

Article  PubMed  PubMed Central  Google Scholar 

Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109:2903–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pua KH, Stiles DT, Sowa ME, Verdine GL. IMPDH2 is an intracellular target of the cyclophilin A and Sanglifehrin A complex. Cell Rep. 2017;18:432–42.

Article  CAS  PubMed  Google Scholar 

Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268:27286–90.

Article  CAS  PubMed  Google Scholar 

Tong X, Zhao F, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev. 2009;19:32–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 2013;3:1252–65.

Article  CAS  PubMed